# Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

> **NCT06803875** · PHASE1,PHASE2 · RECRUITING · sponsor: **Roberto Chiarle** · enrollment: 42 (estimated)

## Conditions studied

- Relapsed Neuroblastoma
- Refractory Neuroblastoma
- High-risk Neuroblastoma

## Interventions

- **BIOLOGICAL:** Autologous hALK.CAR T cells

## Key facts

- **NCT ID:** NCT06803875
- **Lead sponsor:** Roberto Chiarle
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06803875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06803875, "Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06803875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*